Keyphrases
Gemcitabine
100%
Phase II Study
100%
Oxaliplatin
100%
Resectable Pancreatic Cancer
100%
Response Rate
40%
Combination Chemotherapy
40%
Advanced Pancreatic Carcinoma
40%
Median Overall Survival
20%
Anemia
20%
Hematotoxicity
20%
Median Time
20%
Quality of Life Assessment
20%
Time to Progression
20%
Locally Advanced
20%
Clinical Benefit
20%
Overall Survival Time
20%
Previously Untreated Patients
20%
Peripheral Sensory Neuropathy
20%
Global Quality of Life
20%
Metastatic Pancreatic Adenocarcinoma
20%
Single-agent Therapy
20%
Medicine and Dentistry
Gemcitabine
100%
Pancreas Cancer
100%
Oxaliplatin
100%
Infusion
40%
Combination Chemotherapy
40%
Pancreas Carcinoma
40%
Quality of Life
20%
Overall Survival
20%
Anemia
20%
Pancreas Adenocarcinoma
20%
Sensory Neuropathy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Gemcitabine
100%
Pancreas Cancer
100%
Oxaliplatin
100%
Chemotherapy
40%
Pancreas Carcinoma
40%
Overall Survival
20%
Anemia
20%
Sensory Neuropathy
20%
Pancreas Adenocarcinoma
20%